ESC 365 - Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

ESC Premium Access

Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

Session: Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment

Topic: Drug therapy

Speaker: Associate Professor S. Skrtic (Soborg, SE)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Associate Professor Stanko Skrtic

Soborg (Sweden)

0 follower

4 more presentations in this session

Discussant: Best Posters in new targets in cardiovascular drug assessment

Individual-specific corrected QT interval (QTcI) obtained from ECGs recorded at fixed timepoints versus QTcI derived using a wider range of stable heart rates from 24-hour Holter recordings

Speaker: Doctor R. Turner (Durham, US)

Lack of low-density lipoprotein cholesterol (LDL-C) goal attainment among high-risk patients using high or moderate intensity statin therapy in Germany

Speaker: Doctor M. Hatz (Munich, DE)

Role of ivabradine in development of new onset atrial fibrillation in acute coronary syndrome patients

Speaker: Doctor A. Almaghraby (Ras Al Khaimah, AE)

Access the full session

Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment

Speakers: Associate Professor S. Skrtic, Doctor R. Turner, Doctor M. Hatz, Doctor A. Almaghraby

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources